A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma of the head and neck but in patients with recurrent or metastatic disease, EGFR targeting agents have displayed modest efficacy. Vascular endothelial growth factor (VEGF) mediated angiogenesis ha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cohen, Ezra EW, Davis, Darren W., Karrison, Theodore G, Seiwert, Tanguy Y., Wong, Stuart J., Nattam, Sreenivasa, Kozloff, Mark F., Clark, Joseph I., Yan, Duen-Hwa, Liu, Wen, Pierce, Carolyn, Dancey, Janet E, Stenson, Kerstin, Blair, Elizabeth, Dekker, Allison, Vokes, Everett E
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768532/
https://ncbi.nlm.nih.gov/pubmed/19201650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(09)70002-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars